D
Vir Biotechnology, Inc.
VIR
$5.53
$0.254.74%
D
Sell
3/20/2025Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 3/20/2025 due to an increase in the volatility index and valuation index.
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 3/20/2025 due to an increase in the volatility index and valuation index.
E
Sell
3/5/2025Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 3/5/2025 due to a decline in the volatility index.
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 3/5/2025 due to a decline in the volatility index.
D
Sell
2/12/2025Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 2/12/2025 due to an increase in the volatility index and total return index.
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 2/12/2025 due to an increase in the volatility index and total return index.
E
Sell
1/27/2025Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 1/27/2025 due to a decline in the volatility index and valuation index.
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 1/27/2025 due to a decline in the volatility index and valuation index.
D
Sell
1/8/2025Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 1/8/2025 due to an increase in the volatility index and total return index.
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 1/8/2025 due to an increase in the volatility index and total return index.
E
Sell
11/20/2024Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 11/20/2024 due to a decline in the solvency index and volatility index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 12.01 to 7.85.
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 11/20/2024 due to a decline in the solvency index and volatility index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 12.01 to 7.85.
D
Sell
10/24/2024Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 10/24/2024 due to an increase in the volatility index.
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 10/24/2024 due to an increase in the volatility index.
E
Sell
10/9/2024Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 10/9/2024 due to a decline in the total return index and volatility index.
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 10/9/2024 due to a decline in the total return index and volatility index.
D
Sell
9/24/2024Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 9/24/2024 due to an increase in the volatility index.
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 9/24/2024 due to an increase in the volatility index.
E
Sell
9/6/2024Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 9/6/2024 due to a decline in the volatility index and total return index.
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 9/6/2024 due to a decline in the volatility index and total return index.
D
Sell
8/19/2024Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 8/19/2024 due to an increase in the volatility index.
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 8/19/2024 due to an increase in the volatility index.
E
Sell
8/2/2024Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 8/2/2024 due to a decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.4825 to -$1.0157, total revenue declined 94.55% from $56.38M to $3.08M, and EBIT declined 65.28% from -$80.08M to -$132.36M.
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 8/2/2024 due to a decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.4825 to -$1.0157, total revenue declined 94.55% from $56.38M to $3.08M, and EBIT declined 65.28% from -$80.08M to -$132.36M.
D
Sell
7/31/2024Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 7/31/2024 due to an increase in the total return index and volatility index.
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 7/31/2024 due to an increase in the total return index and volatility index.
E
Sell
7/16/2024Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 7/16/2024 due to a decline in the volatility index.
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 7/16/2024 due to a decline in the volatility index.
D
Sell
6/28/2024Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 6/28/2024 due to an increase in the volatility index and total return index.
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 6/28/2024 due to an increase in the volatility index and total return index.
E
Sell
6/12/2024Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 6/12/2024 due to a decline in the volatility index and total return index.
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D- on 6/12/2024 due to a decline in the volatility index and total return index.
D
Sell
5/24/2024Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 5/24/2024 due to an increase in the volatility index and total return index.
Vir Biotechnology, Inc. (VIR) was upgraded to D- from E+ on 5/24/2024 due to an increase in the volatility index and total return index.
E
Sell
5/7/2024Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D on 5/7/2024 due to a major decline in the efficiency index and volatility index. Total capital declined 2.7% from $1.71B to $1.67B.
Vir Biotechnology, Inc. (VIR) was downgraded to E+ from D on 5/7/2024 due to a major decline in the efficiency index and volatility index. Total capital declined 2.7% from $1.71B to $1.67B.
D
Sell
2/14/2024Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to D from D- on 2/14/2024 due to an increase in the solvency index, volatility index and total return index.
Vir Biotechnology, Inc. (VIR) was upgraded to D from D- on 2/14/2024 due to an increase in the solvency index, volatility index and total return index.
D
Sell
12/19/2023Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to D- from D on 12/19/2023 due to a decline in the volatility index and total return index.
Vir Biotechnology, Inc. (VIR) was downgraded to D- from D on 12/19/2023 due to a decline in the volatility index and total return index.
D
Sell
12/4/2023Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to D from D- on 12/4/2023 due to an increase in the volatility index and valuation index.
Vir Biotechnology, Inc. (VIR) was upgraded to D from D- on 12/4/2023 due to an increase in the volatility index and valuation index.
D
Sell
10/11/2023Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to D- from D on 10/11/2023 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 209.46% from -$125.78M to -$389.25M, total revenue declined 93.97% from $62.96M to $3.8M, and EBIT declined 50.09% from -$143.37M to -$215.19M.
Vir Biotechnology, Inc. (VIR) was downgraded to D- from D on 10/11/2023 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 209.46% from -$125.78M to -$389.25M, total revenue declined 93.97% from $62.96M to $3.8M, and EBIT declined 50.09% from -$143.37M to -$215.19M.
D
Sell
5/9/2023Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to D from D+ on 5/9/2023 due to a decline in the volatility index, total return index and efficiency index.
Vir Biotechnology, Inc. (VIR) was downgraded to D from D+ on 5/9/2023 due to a decline in the volatility index, total return index and efficiency index.
D
Sell
4/21/2023Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to D+ from D on 4/21/2023 due to an increase in the volatility index.
Vir Biotechnology, Inc. (VIR) was upgraded to D+ from D on 4/21/2023 due to an increase in the volatility index.
D
Sell
4/5/2023Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to D from D+ on 4/5/2023 due to a decline in the volatility index, total return index and solvency index.
Vir Biotechnology, Inc. (VIR) was downgraded to D from D+ on 4/5/2023 due to a decline in the volatility index, total return index and solvency index.
D
Sell
3/6/2023Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to D+ from C- on 3/6/2023 due to a decline in the volatility index and total return index.
Vir Biotechnology, Inc. (VIR) was downgraded to D+ from C- on 3/6/2023 due to a decline in the volatility index and total return index.
C
Hold
3/1/2023Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to C- from C on 3/1/2023 due to a significant decline in the growth index, solvency index and valuation index. Earnings per share declined from $1.3 to -$0.763, EBIT declined 137.91% from $194.96M to -$73.9M, and total revenue declined 86.81% from $374.56M to $49.41M.
Vir Biotechnology, Inc. (VIR) was downgraded to C- from C on 3/1/2023 due to a significant decline in the growth index, solvency index and valuation index. Earnings per share declined from $1.3 to -$0.763, EBIT declined 137.91% from $194.96M to -$73.9M, and total revenue declined 86.81% from $374.56M to $49.41M.
C
Hold
11/7/2022Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to C from D+ on 11/7/2022 due to a significant increase in the growth index, solvency index and efficiency index. Total revenue increased 1,021.9% from -$40.63M to $374.56M, net income increased 329.19% from -$76.49M to $175.31M, and earnings per share increased from -$0.58 to $1.3.
Vir Biotechnology, Inc. (VIR) was upgraded to C from D+ on 11/7/2022 due to a significant increase in the growth index, solvency index and efficiency index. Total revenue increased 1,021.9% from -$40.63M to $374.56M, net income increased 329.19% from -$76.49M to $175.31M, and earnings per share increased from -$0.58 to $1.3.
D
Sell
8/12/2022Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to D+ from C- on 8/12/2022 due to a significant decline in the growth index, solvency index and volatility index. EBIT declined 122.22% from $1.01B to -$225.22M, earnings per share declined from $3.85 to -$0.58, and total revenue declined 103.3% from $1.23B to -$40.63M.
Vir Biotechnology, Inc. (VIR) was downgraded to D+ from C- on 8/12/2022 due to a significant decline in the growth index, solvency index and volatility index. EBIT declined 122.22% from $1.01B to -$225.22M, earnings per share declined from $3.85 to -$0.58, and total revenue declined 103.3% from $1.23B to -$40.63M.
C
Hold
3/21/2022Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to C- from C on 3/21/2022 due to a decline in the total return index and volatility index.
Vir Biotechnology, Inc. (VIR) was downgraded to C- from C on 3/21/2022 due to a decline in the total return index and volatility index.
C
Hold
3/4/2022Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to C from D on 3/4/2022 due to a significant increase in the valuation index, efficiency index and growth index. EBIT increased 1,160.6% from -$53.39M to $566.2M, total revenue increased 684.38% from $103.62M to $812.75M, and earnings per share increased from $0.82 to $3.927.
Vir Biotechnology, Inc. (VIR) was upgraded to C from D on 3/4/2022 due to a significant increase in the valuation index, efficiency index and growth index. EBIT increased 1,160.6% from -$53.39M to $566.2M, total revenue increased 684.38% from $103.62M to $812.75M, and earnings per share increased from $0.82 to $3.927.
D
Sell
11/23/2021Upgraded
Vir Biotechnology, Inc. (VIR) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
Vir Biotechnology, Inc. (VIR) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
Vir Biotechnology, Inc. (VIR) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the efficiency index and valuation index.
Vir Biotechnology, Inc. (VIR) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the efficiency index and valuation index.
D
Sell
1/7/2020None
Vir Biotechnology, Inc. (VIR) was downgraded to D from U on 01/07/2020.
Vir Biotechnology, Inc. (VIR) was downgraded to D from U on 01/07/2020.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
